High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C

doi:10.3748/wjg.v12.i4.556

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

Reference Citation Analysis (1)

(0)

(3931)

(16)

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Viral Hepatitis

World J Gastroenterol. Jan 28, 2006; 12(4): 556-560
Published online Jan 28, 2006. doi: 10.3748/wjg.v12.i4.556

Full Size Figure Download Figure

Figure 1 Effectiveness of IFN and serum leptin level in subjects with a low viremia level. NR: Non-responder group for IFN therapy; SR: Sustained responder group. ^aP < 0.05, NR vs SR. Mann-Whitney U-test.

Citation: Eguchi Y, Mizuta T, Yasutake T, Hisatomi A, Iwakiri R, Ozaki I, Fujimoto K. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006; 12(4): 556-560
URL: https://www.wjgnet.com/1007-9327/full/v12/i4/556.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i4.556

Eguchi Y, Mizuta T, Yasutake T, Hisatomi A, Iwakiri R, Ozaki I, Fujimoto K. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006; 12(4): 556-560 [PMID: 16489668 DOI: 10.3748/wjg.v12.i4.556]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.